Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study Explores Anti-CD20 Activity in CBP-Mutant DLBCL

Publish date:: November 3, 2019

Key clinical point: Pre-clinical data suggests patients with CREB-binding protein (CBP)-mutant diffuse large B-cell lymphoma (DLBCL) may benefit from intensified anti-CD20 therapy.

Major finding: In cellular studies, CBP or EP300 depletion resulted in lower direct cell death and complement dependent cell death in response to obinutuzumab and rituximab.

Study details: A pre-clinical study examining the effects of transcriptional coactivator depletion on anti-CD20 antibody activity in DLBCL.

Disclosures: The study was funded by the Swedish Cancer Society, the Swedish government, and foundations. The authors reported financial affiliations with Respiratorius AB and Roche.

Citation:

Scialdone A et al. Exp Hematol. 2019 Oct 25. doi: 10.1016/j.exphem.2019.10.004.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,